|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1 Suppl 3
|
|
pubmed:dateCreated |
2002-3-14
|
|
pubmed:abstractText |
Chemotherapy has been the cornerstone of treatment of advanced urothelial cancer. For a decade, the combination regimen of methotrexate/vinblastine/doxorubicin/cisplatin has been considered the standard for these patients. The need for improved efficacy and reduced toxicity of a predominantly palliative therapy has propelled efforts for new drug development. Of the newly identified agents with documented activity, both gemcitabine and paclitaxel have been evaluated with a platinum and have been incorporated into multiagent chemotherapy combinations. Phase II data from two gemcitabine-based triplets are currently available. Combination gemcitabine/paclitaxel/cisplatin and gemcitabine/paclitaxel/carboplatin have high levels of activity with overall and complete response rates of 76% and 26%, respectively, for the former and 68% and 32%, respectively, for the latter combination. The role of gemcitabine-based multiagent combinations compared with standard therapy awaits evaluation in prospectively randomized trials.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0093-7754
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002, Elsevier Science (USA). All rights reserved.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
20-4
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11894004-Antimetabolites, Antineoplastic,
pubmed-meshheading:11894004-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:11894004-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11894004-Carboplatin,
pubmed-meshheading:11894004-Carcinoma, Transitional Cell,
pubmed-meshheading:11894004-Cisplatin,
pubmed-meshheading:11894004-Clinical Trials, Phase II as Topic,
pubmed-meshheading:11894004-Deoxycytidine,
pubmed-meshheading:11894004-Doxorubicin,
pubmed-meshheading:11894004-Forecasting,
pubmed-meshheading:11894004-Humans,
pubmed-meshheading:11894004-Methotrexate,
pubmed-meshheading:11894004-Neoplasm Metastasis,
pubmed-meshheading:11894004-Neoplasm Staging,
pubmed-meshheading:11894004-Paclitaxel,
pubmed-meshheading:11894004-Survival Analysis,
pubmed-meshheading:11894004-Treatment Outcome,
pubmed-meshheading:11894004-Urinary Bladder Neoplasms,
pubmed-meshheading:11894004-Vinblastine
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Novel gemcitabine-containing triplets in the management of urothelial cancer.
|
|
pubmed:affiliation |
Division of Hematology/Oncology, Wayne State University and the Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
|
|
pubmed:publicationType |
Journal Article,
Review
|
